Humoral Immune Response to SARS-CoV-2 in Iceland.
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
29 10 2020
29 10 2020
Historique:
pubmed:
2
9
2020
medline:
6
11
2020
entrez:
2
9
2020
Statut:
ppublish
Résumé
Little is known about the nature and durability of the humoral immune response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We measured antibodies in serum samples from 30,576 persons in Iceland, using six assays (including two pan-immunoglobulin [pan-Ig] assays), and we determined that the appropriate measure of seropositivity was a positive result with both pan-Ig assays. We tested 2102 samples collected from 1237 persons up to 4 months after diagnosis by a quantitative polymerase-chain-reaction (qPCR) assay. We measured antibodies in 4222 quarantined persons who had been exposed to SARS-CoV-2 and in 23,452 persons not known to have been exposed. Of the 1797 persons who had recovered from SARS-CoV-2 infection, 1107 of the 1215 who were tested (91.1%) were seropositive; antiviral antibody titers assayed by two pan-Ig assays increased during 2 months after diagnosis by qPCR and remained on a plateau for the remainder of the study. Of quarantined persons, 2.3% were seropositive; of those with unknown exposure, 0.3% were positive. We estimate that 0.9% of Icelanders were infected with SARS-CoV-2 and that the infection was fatal in 0.3%. We also estimate that 56% of all SARS-CoV-2 infections in Iceland had been diagnosed with qPCR, 14% had occurred in quarantined persons who had not been tested with qPCR (or who had not received a positive result, if tested), and 30% had occurred in persons outside quarantine and not tested with qPCR. Our results indicate that antiviral antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis. We estimate that the risk of death from infection was 0.3% and that 44% of persons infected with SARS-CoV-2 in Iceland were not diagnosed by qPCR.
Sections du résumé
BACKGROUND
Little is known about the nature and durability of the humoral immune response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
METHODS
We measured antibodies in serum samples from 30,576 persons in Iceland, using six assays (including two pan-immunoglobulin [pan-Ig] assays), and we determined that the appropriate measure of seropositivity was a positive result with both pan-Ig assays. We tested 2102 samples collected from 1237 persons up to 4 months after diagnosis by a quantitative polymerase-chain-reaction (qPCR) assay. We measured antibodies in 4222 quarantined persons who had been exposed to SARS-CoV-2 and in 23,452 persons not known to have been exposed.
RESULTS
Of the 1797 persons who had recovered from SARS-CoV-2 infection, 1107 of the 1215 who were tested (91.1%) were seropositive; antiviral antibody titers assayed by two pan-Ig assays increased during 2 months after diagnosis by qPCR and remained on a plateau for the remainder of the study. Of quarantined persons, 2.3% were seropositive; of those with unknown exposure, 0.3% were positive. We estimate that 0.9% of Icelanders were infected with SARS-CoV-2 and that the infection was fatal in 0.3%. We also estimate that 56% of all SARS-CoV-2 infections in Iceland had been diagnosed with qPCR, 14% had occurred in quarantined persons who had not been tested with qPCR (or who had not received a positive result, if tested), and 30% had occurred in persons outside quarantine and not tested with qPCR.
CONCLUSIONS
Our results indicate that antiviral antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis. We estimate that the risk of death from infection was 0.3% and that 44% of persons infected with SARS-CoV-2 in Iceland were not diagnosed by qPCR.
Identifiants
pubmed: 32871063
doi: 10.1056/NEJMoa2026116
pmc: PMC7494247
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1724-1734Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Massachusetts Medical Society.
Références
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
Immunity. 2007 Sep;27(3):384-92
pubmed: 17892847
J Adolesc Health. 2020 Sep;67(3):362-368
pubmed: 32674964
J Clin Virol. 2020 Aug;129:104512
pubmed: 32563180
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Wellcome Open Res. 2020 Jun 11;5:139
pubmed: 33748431
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227